Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
18.10
-0.32 (-1.74%)
At close: Aug 14, 2026, 4:00 PM EDT
17.78
-0.32 (-1.77%)
After-hours: Aug 14, 2026, 7:34 PM EDT
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
According to 24 analysts polled by S&P Global, Sarepta Therapeutics stock has a consensus rating of "Hold" and an average price target of $22.09. The average 1-year stock price forecast is 22.04% higher than the current stock price, while the lowest is $5.00 (-72.38%) and the highest is $38 (+109.94%).
Price Target: $22.09 (+22.04%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Sarepta Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 6 | 6 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 13 | 13 | 12 | 13 | 13 | 11 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 3 | 3 | 3 | 3 | 3 | 3 |
| Total | 25 | 25 | 25 | 24 | 24 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI | Evercore ISI | Hold Maintains $19 | Hold | Maintains | $19 | +4.97% | Aug 10, 2026 |
| Barclays | Barclays | Hold Maintains $20 | Hold | Maintains | $20 | +10.50% | Aug 7, 2026 |
| Bank of America Securities | Bank of America Securities | Sell Reiterates $19 → $18 | Sell | Reiterates | $19 → $18 | -0.55% | Aug 6, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $21 | Hold | Maintains | $21 | +16.02% | Aug 6, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $37 → $35 | Buy | Maintains | $37 → $35 | +93.37% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
1.84B
from 2.20B
Decreased by -16.42%
Revenue Next Year
1.38B
from 1.84B
Decreased by -24.83%
EPS This Year
4.39
from -5.05
EPS Next Year
2.57
from 4.39
Decreased by -41.45%
EPS and Forward PE are based on non-GAAP adjusted numbers.